| ZW6584A1
              (en)
            
            * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives | 
        
          | ES8702880A1
              (es)
            
            * | 1984-04-17 | 1987-01-16 | Glaxo Group Ltd | Un procedimiento para la produccion de compuestos de fenetanolamina. | 
        
          | GB8525321D0
              (en)
            
            * | 1985-10-15 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds | 
        
          | US4943591A
              (en)
            
            * | 1984-10-17 | 1990-07-24 | Glaxo Group Limited | Dichloroaniline derivatives | 
        
          | EP0220054A3
              (en)
            
            * | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives | 
        
          | EP0223410A3
              (en)
            
            * | 1985-10-16 | 1987-11-19 | Glaxo Group Limited | Ethanolamine derivatives | 
        
          | GB8525483D0
              (en)
            
            * | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds | 
        
          | GB8525484D0
              (en)
            
            * | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds | 
        
          | EP0278727A3
              (en)
            
            * | 1987-02-10 | 1990-03-14 | Glaxo Group Limited | 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-(substituted amino)ethanol derivatives and their use in the treatment of respiratory disease | 
        
          | EP0286242A3
              (en)
            
            * | 1987-03-12 | 1989-08-09 | Glaxo Group Limited | Ethanolamine derivates, processes for their preparation and pharmaceutical compositions containing them | 
        
          | GB8718938D0
              (en)
            
            * | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds | 
        
          | GB8718940D0
              (en)
            
            * | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds | 
        
          | IE883400L
              (en)
            
            * | 1987-11-13 | 1989-05-13 | Fuisz Technologies Ltd | Phenethanolamine derivatives | 
        
          | NZ227365A
              (en)
            
            * | 1987-12-18 | 1990-10-26 | Glaxo Group Ltd | Aromatic amino ethers and pharmaceutical compositions | 
        
          | ZA889405B
              (en)
            
            * | 1987-12-18 | 1989-12-27 | Glaxo Group Ltd | Ethanolamine derivatives | 
        
          | GB2230775A
              (en)
            
            * | 1989-04-24 | 1990-10-31 | Glaxo Group Ltd | Phenethanolamine compounds | 
        
          | GB8909273D0
              (en)
            
            * | 1989-04-24 | 1989-06-07 | Glaxo Group Ltd | Chemical compounds | 
        
          | US5290815A
              (en)
            
            * | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy | 
        
          | CA2024789C
              (en)
            
            * | 1989-09-07 | 2001-02-06 | Malcolm Johnson | Compounds for the treatment of inflammation and allergy | 
        
          | US5208226A
              (en)
            
            * | 1989-09-08 | 1993-05-04 | Glaxo Group Limited | Medicaments | 
        
          | AU644094B2
              (en)
            
            * | 1989-09-08 | 1993-12-02 | Glaxo Group Limited | Medicaments | 
        
          | IL95590A
              (en)
            
            * | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate | 
        
          | US5270305A
              (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments | 
        
          | IL95936A
              (en)
            
            * | 1989-10-10 | 1996-01-19 | Glaxo Group Ltd | ) R (-) - (- Hydroxy- (A-]]] 6-) 4- Phenylbutoxy (xyl [amino] methyl [-1,3-benzenedimethanol, its preparation and pharmaceutical preparations containing it | 
        
          | SK280968B6
              (sk) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Balenie medikamentu na použite v inhalačnom prístroji | 
        
          | US6536427B2
              (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device | 
        
          | UA26230A
              (uk) | 1990-03-02 | 1999-07-19 | Глексо Груп Лімітед | Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок | 
        
          | US5919827A
              (en)
            
            * | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol | 
        
          | GB9026005D0
              (en)
            
            * | 1990-11-29 | 1991-01-16 | Glaxo Group Ltd | Drug material suitable for micronisation | 
        
          | CN1056974C
              (zh)
            
            * | 1992-02-11 | 2000-10-04 | 格拉克索公司 | 适宜于微粒化的药物材料的制备方法 | 
        
          | AU1229892A
              (en)
            
            * | 1992-02-11 | 1993-09-03 | Glaxo Group Limited | Benzenedimethanol derivative suitable for micronisation | 
        
          | AP323A
              (en)
            
            * | 1992-05-08 | 1994-03-07 | Glaxo Group Ltd | Drug material suitable for micronisation. | 
        
          | GB9215274D0
              (en)
            
            * | 1992-07-17 | 1992-09-02 | Scras | Derivatives of(phenylethyl-beta-ol)amine | 
        
          | ES2065269B1
              (es)
            
            * | 1993-05-11 | 1995-10-01 | S A L V A T Lab Sa | 6-(4-(fenilbutoxi) hexilaminometil-4-hidroxi-a1,a3-bencenodimetanol. procedimiento para la obtencion del mismo y nuevos intermedios utilizados en su preparacion. | 
        
          | AU692809B2
              (en)
            
            * | 1993-12-10 | 1998-06-18 | Novartis Ag | Novel substituted oxazolidines | 
        
          | GB9507768D0
              (en)
            
            * | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus | 
        
          | RO119116B1
              (ro) | 1995-04-14 | 2004-04-30 | Glaxo Wellcome Inc. | Inhalator pentru dozarea salmeterolului | 
        
          | AP791A
              (en)
            
            * | 1995-04-14 | 1999-12-17 | Glaxo Wellcome Inc | Metered dose inhaler for albuterol. | 
        
          | SK139197A3
              (en)
            
            * | 1995-04-14 | 1998-04-08 | Glaxo Wellcome Inc | Metered dose inhaler for beclomethasone dipropionate | 
        
          | EP1769819A3
              (en) | 1995-04-14 | 2013-05-22 | GlaxoSmithKline LLC | Metered dose inhaler for fluticasone propionate | 
        
          | US6632955B1
              (en) | 1996-12-02 | 2003-10-14 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same | 
        
          | US6254882B1
              (en) | 1997-09-16 | 2001-07-03 | Sepracor Inc. | Methods and compositions for treating pulmonary disorders using optically pure (S)—salmeterol | 
        
          | CA2333903A1
              (en)
            
            * | 1998-06-01 | 1999-12-09 | Anthony J. Verbiscar | Topical transdermal treatments | 
        
          | ES2142771B1
              (es)
            
            * | 1998-09-28 | 2001-01-01 | Vita Invest Sa | Nuevos derivados de la 6-(4-fenil-butoxi) hexilamina y procedimiento para la obtencion de salmeterol. | 
        
          | AU4417500A
              (en) | 1999-04-14 | 2000-11-14 | Glaxo Group Limited | Pharmaceutical aerosol formulation | 
        
          | TR200201317T2
              (tr)
            
            * | 1999-08-21 | 2002-11-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Sinerjistik kombinasyon. | 
        
          | GB0009609D0
              (en)
            
            * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic compositions | 
        
          | GB0009613D0
              (en)
            
            * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions | 
        
          | GB0014546D0
              (en)
            
            * | 2000-06-14 | 2000-08-09 | Glaxo Group Ltd | A novel process | 
        
          | GB0015043D0
              (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser | 
        
          | GB0019172D0
              (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds | 
        
          | US6858593B2
              (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions | 
        
          | CA2417825C
              (en)
            
            * | 2000-08-05 | 2008-07-22 | Glaxo Group Limited | 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl)oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent | 
        
          | US6787532B2
              (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives | 
        
          | US6858596B2
              (en)
            
            * | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative | 
        
          | US6777400B2
              (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions | 
        
          | US6759398B2
              (en)
            
            * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative | 
        
          | US6750210B2
              (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative | 
        
          | US6777399B2
              (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions | 
        
          | WO2002024552A2
              (en) | 2000-09-18 | 2002-03-28 | Glaxo Group Limited | Coated can for a metered dose inhaler | 
        
          | GB0103630D0
              (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds | 
        
          | JP2004526720A
              (ja)
            
            * | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト | 
        
          | BR0208012A
              (pt)
            
            * | 2001-03-20 | 2004-03-02 | Glaxo Group Ltd | Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma | 
        
          | ATE381537T1
              (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten | 
        
          | UA77656C2
              (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent | 
        
          | US6667344B2
              (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods | 
        
          | US20030055026A1
              (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof | 
        
          | MY137522A
              (en) | 2001-04-30 | 2009-02-27 | Glaxo Group Ltd | Novel anti-inflammatory androstane derivatives. | 
        
          | NZ530278A
              (en)
            
            * | 2001-06-01 | 2006-06-30 | Tendskin Company | Topical composition containing a salicylate derivative for veterinary use in treating dermatological disorders | 
        
          | US6680345B2
              (en) | 2001-09-14 | 2004-01-20 | Boehringer Ingelheim Pharma Kg | Salicylic acid salts of salmeterol | 
        
          | CA2460440A1
              (en)
            
            * | 2001-09-14 | 2003-03-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salicylic acid salts, processes for preparing them and their use as pharmaceutical compositions | 
        
          | SI2042168T1
              (sl)
            
            * | 2001-09-14 | 2014-01-31 | Glaxo Group Limited | Inhalacijska formulacija, ki obsega fenetanolaminske derivate, za zdravljenje respiratornih bolezni | 
        
          | TWI249515B
              (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists | 
        
          | US20030229058A1
              (en)
            
            * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists | 
        
          | US6653323B2
              (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists | 
        
          | US20050175545A1
              (en)
            
            * | 2002-02-04 | 2005-08-11 | Keith Biggadike | Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist | 
        
          | GB0202635D0
              (en)
            
            * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative | 
        
          | US6756508B2
              (en) | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments | 
        
          | JP2005519110A
              (ja)
            
            * | 2002-03-04 | 2005-06-30 | ベーリンガー  インゲルハイム  ファルマ  ゲゼルシャフト  ミット  ベシュレンクテル  ハフツング  ウント  コンパニー  コマンディトゲゼルシャフト | 新規なケイ皮酸塩、その調製方法及び医薬品としての使用 | 
        
          | US6835857B2
              (en) | 2002-03-05 | 2004-12-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene | 
        
          | DE10209583B4
              (de)
            
            * | 2002-03-05 | 2006-01-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von 4-(6-Bromhexyloxy)-butylbenzol | 
        
          | US7378438B2
              (en)
            
            * | 2002-04-19 | 2008-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | 
        
          | DE60318193T2
              (de)
            
            * | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate | 
        
          | WO2003099764A1
              (en) | 2002-05-28 | 2003-12-04 | Theravance, Inc. | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS | 
        
          | GB2389530B
              (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions | 
        
          | GB0217225D0
              (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds | 
        
          | US20040023935A1
              (en)
            
            * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same | 
        
          | DE10249576B3
              (de)
            
            * | 2002-10-24 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von (R)-Salbutamol | 
        
          | GB0225030D0
              (en)
            
            * | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds | 
        
          | DE60320007T2
              (de) | 2002-10-28 | 2009-06-18 | Glaxo Group Ltd., Greenford | Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen | 
        
          | GB0225535D0
              (en)
            
            * | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds | 
        
          | US20040109826A1
              (en)
            
            * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof | 
        
          | JP2006511297A
              (ja)
            
            * | 2002-12-18 | 2006-04-06 | グラクソ グループ リミテッド | ベント型マウスピースを有する投薬システム | 
        
          | PE20040950A1
              (es)
            
            * | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS | 
        
          | GB0303396D0
              (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds | 
        
          | EP1615881A2
              (en)
            
            * | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | 
        
          | US20040226556A1
              (en)
            
            * | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin | 
        
          | DE602004021921D1
              (de)
            
            * | 2003-05-28 | 2009-08-20 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten | 
        
          | TWI359675B
              (en)
            
            * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions | 
        
          | US20050113318A1
              (en)
            
            * | 2003-07-31 | 2005-05-26 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | 
        
          | US20050026884A1
              (en)
            
            * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | 
        
          | US20090285900A1
              (en)
            
            * | 2003-07-31 | 2009-11-19 | Robinson Cynthia B | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease | 
        
          | US8198354B2
              (en) | 2003-08-11 | 2012-06-12 | Glaxo Group Limited | Pharmaceutical metered dose inhaler and methods relating thereto | 
        
          | GB0319826D0
              (en)
            
            * | 2003-08-22 | 2003-09-24 | Glaxo Group Ltd | Process | 
        
          | CA2537185A1
              (en)
            
            * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv | 
        
          | TW200526547A
              (en)
            
            * | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists | 
        
          | GB0324654D0
              (en)
            
            * | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds | 
        
          | GB0324886D0
              (en)
            
            * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds | 
        
          | EP1694655A2
              (en)
            
            * | 2003-11-26 | 2006-08-30 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors | 
        
          | SE0303570L
              (sv)
            
            * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Fukt-känslig medicinsk produkt | 
        
          | CA2547782A1
              (en)
            
            * | 2003-12-03 | 2005-06-16 | Microdrug Ag | Medical product containing tiotropium | 
        
          | SE0303270L
              (sv)
            
            * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium | 
        
          | GB0329182D0
              (en)
            
            * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds | 
        
          | TW200531692A
              (en)
            
            * | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists | 
        
          | JP2007528889A
              (ja)
            
            * | 2004-03-12 | 2007-10-18 | シプラ・リミテッド | 吸入製剤 | 
        
          | JP2008501705A
              (ja)
            
            * | 2004-06-03 | 2008-01-24 | セラヴァンス,  インコーポレーテッド | ジアミンβ2アドレナリン作用性レセプターアゴニスト | 
        
          | EP1778638A1
              (en)
            
            * | 2004-07-21 | 2007-05-02 | Theravance, Inc. | Diaryl ether beta2 adrenergic receptor agonists | 
        
          | JP2008512470A
              (ja)
            
            * | 2004-09-10 | 2008-04-24 | セラヴァンス,  インコーポレーテッド | アミジン置換アリールアニリン化合物 | 
        
          | EP1949891A1
              (en) | 2004-10-12 | 2008-07-30 | Generics (UK) Limited | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister | 
        
          | CA2581999C
              (en) | 2004-10-12 | 2013-04-23 | Generics (Uk) Limited | Preparation of suspension aerosol formulations | 
        
          | GB0507165D0
              (en)
            
            * | 2005-04-08 | 2005-05-18 | Glaxo Group Ltd | Novel crystalline pharmaceutical product | 
        
          | ES2265276B1
              (es)
            
            * | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. | 
        
          | DE102005033732B4
              (de)
            
            * | 2005-05-27 | 2014-02-13 | Grünenthal GmbH | Trennung stereoisomerer N,N-Dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkane | 
        
          | WO2007008427A2
              (en)
            
            * | 2005-07-08 | 2007-01-18 | Xemplar Pharmaceuticals, Llc | Aerosol compositions and methods | 
        
          | US8429052B2
              (en)
            
            * | 2005-07-19 | 2013-04-23 | Lincoln National Life Insurance Company | Method and system for providing employer-sponsored retirement plan | 
        
          | TWI274641B
              (en)
            
            * | 2005-08-30 | 2007-03-01 | Rexon Ind Corp Ltd | Cutting machine | 
        
          | WO2007031838A1
              (en) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors | 
        
          | ES2570597T3
              (es) | 2005-10-17 | 2016-05-19 | Generics Uk Ltd | Proceso e intermedios para la preparación de Salmeterol | 
        
          | JP2009512676A
              (ja) | 2005-10-19 | 2009-03-26 | ランバクシー  ラボラトリーズ  リミテッド | ムスカリン性受容体アンタゴニストの医薬組成物 | 
        
          | US20090054382A1
              (en)
            
            * | 2005-10-19 | 2009-02-26 | Abhijit Ray | Compositions of phosphodiesterase type iv inhibitors | 
        
          | WO2007079466A2
              (en)
            
            * | 2006-01-04 | 2007-07-12 | Nano Mist International, Llc | Air driven delivery system for sprayable media | 
        
          | GB0602778D0
              (en)
            
            * | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound | 
        
          | EP2001881A2
              (en)
            
            * | 2006-03-07 | 2008-12-17 | Endacea, Inc. | Compositions and methods for treating respiratory disorders | 
        
          | ES2296516B1
              (es)
            
            * | 2006-04-27 | 2009-04-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. | 
        
          | US20070286814A1
              (en)
            
            * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations | 
        
          | GB0615108D0
              (en)
            
            * | 2006-07-28 | 2006-09-06 | Glaxo Group Ltd | Novel formulations | 
        
          | EP2322507A1
              (en) | 2006-08-22 | 2011-05-18 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors | 
        
          | US20100029728A1
              (en)
            
            * | 2006-09-22 | 2010-02-04 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors | 
        
          | AU2007298549A1
              (en)
            
            * | 2006-09-22 | 2008-03-27 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV | 
        
          | ES2302447B1
              (es)
            
            * | 2006-10-20 | 2009-06-12 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. | 
        
          | ES2306595B1
              (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. | 
        
          | EP1958947A1
              (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 | 
        
          | CN103497185A
              (zh)
            
            * | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 | 
        
          | EP2124943A1
              (en)
            
            * | 2007-03-14 | 2009-12-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors | 
        
          | US20080319086A1
              (en)
            
            * | 2007-06-20 | 2008-12-25 | Protia, Llc | Deuterium-enriched salmeterol | 
        
          | US20090048155A1
              (en) | 2007-08-15 | 2009-02-19 | Endacea, Inc. | Methods for preventing and treating tissue injury and sepsis associated with Yersinia pestis infection | 
        
          | ES2320961B1
              (es) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2. | 
        
          | EP2222676A4
              (en) | 2007-12-21 | 2011-10-26 | Endacea Inc | A1-adenosine receptor antagonistic | 
        
          | US8483831B1
              (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation | 
        
          | AU2009241628A1
              (en) | 2008-02-26 | 2009-11-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations | 
        
          | US20100055045A1
              (en)
            
            * | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations | 
        
          | EP2111861A1
              (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors | 
        
          | JP2011519699A
              (ja)
            
            * | 2008-05-09 | 2011-07-14 | インノブアトイブエ  プルモナルイ  ソルウトイオンス,インコーポレイティッド | 気管支樹の治療のためのシステム、アセンブリ、及び方法 | 
        
          | EP2127641A1
              (en)
            
            * | 2008-05-26 | 2009-12-02 | Inke, S.A. | Micronisable form of salmeterol xinafoate | 
        
          | UY32297A
              (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico | 
        
          | EP2221055A1
              (en)
            
            * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function | 
        
          | EP2228368A1
              (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one | 
        
          | EP2435024B1
              (en)
            
            * | 2009-05-29 | 2016-07-06 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems | 
        
          | US8815258B2
              (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents | 
        
          | WO2011056684A2
              (en) | 2009-10-27 | 2011-05-12 | Innovative Pulmonary Solutions, Inc. | Delivery devices with coolable energy emitting assemblies | 
        
          | US8911439B2
              (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same | 
        
          | WO2011060200A1
              (en) | 2009-11-11 | 2011-05-19 | Innovative Pulmonary Solutions, Inc. | Systems, apparatuses, and methods for treating tissue and controlling stenosis | 
        
          | TR201000685A2
              (tr) | 2010-01-29 | 2011-08-22 | Bi̇lgi̇ç Mahmut | Salmeterol ve flutikazon içeren farmasötik preparatlar. | 
        
          | NZ603136A
              (en) | 2010-05-10 | 2014-11-28 | Gilead Sciences Inc | Bifunctional quinoline derivatives | 
        
          | WO2011143106A1
              (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bi - functional pyrazolopyridine compounds | 
        
          | PH12013500198A1
              (en) | 2010-07-30 | 2013-03-11 | Ranbaxy Laboratories Ltd | Matrix metalloproteinase inhibitors | 
        
          | WO2012032546A2
              (en) | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates | 
        
          | JP2013540754A
              (ja) | 2010-09-24 | 2013-11-07 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 | 
        
          | EP2578570A1
              (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. | 
        
          | EP2641900A1
              (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | 
        
          | CN103864629A
              (zh)
            
            * | 2012-12-13 | 2014-06-18 | 天津金耀集团有限公司 | 昔萘酸沙美特罗的精制方法 | 
        
          | US9398933B2
              (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation | 
        
          | MX361286B
              (es) | 2013-03-15 | 2018-12-03 | Pearl Therapeutics Inc | Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas. | 
        
          | US20160129207A1
              (en) | 2013-06-17 | 2016-05-12 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhalation composition filling method | 
        
          | CN104744271B
              (zh)
            
            * | 2013-12-26 | 2016-08-31 | 成都伊诺达博医药科技有限公司 | 一种合成维兰特罗的新工艺 | 
        
          | US9447067B2
              (en) | 2014-10-03 | 2016-09-20 | Amphastar Pahmaceuticals, Inc. | Method of preparing intermediate of salmeterol | 
        
          | WO2016142582A1
              (en) | 2015-03-11 | 2016-09-15 | Fermion Oy | Process for the preparation of crystalline salmeterol and its xinafoate salt | 
        
          | CN114685291B
              (zh)
            
            * | 2020-12-30 | 2025-06-17 | 天津药业研究院股份有限公司 | 沙美特罗的制备方法和应用 | 
        
          | CR20240063A
              (es) | 2021-07-09 | 2024-04-25 | Astrazeneca Pharmaceuticals Lp | Composiciones, métodos y sistemas para la administración de fármacos en aerosol | 
        
          | WO2023119093A1
              (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery | 
        
          | EP4543833A1
              (en)
            
            * | 2022-06-26 | 2025-04-30 | Alexander Shulgin Research Institute, Inc. | N-substituted phenylalkylamines and their use as therapeutic agents |